News | August 07, 2014

Transluminal Technologies Receives CE Mark Approval for Velox CD Vascular Closure Device

Transluminal Technologies LLC CE mark velox CD Vascular Closure Device

August 7, 2014 — Transluminal Technologies LLC, a Syracuse, NY-based medical device company, received CE mark approval for the velox CD Vascular Closure Device. Velox CD provides a safe and predictable means for achieving immediate hemostasis following percutaneous femoral procedures. The single size velox CD is indicated for closing arteriotomies broadly ranging in size from 5 French to 8 French.

Velox CD utilizes patented mechanisms to provide an easy-to-use, single-use instrument to deliver an implant to the vessel wall, thereby avoiding the need for time-consuming manual compression and allowing for shorter patient time-to-ambulation. The implant is wholly made from a proprietary magnesium alloy designed to bioabsorb rapidly after implantation. The implant's intraluminal portion dissolves within 24 hours, while the remainder is completely resorbed within two weeks.

CE mark approval has been granted on the strength of a pivotal clinical trial in which the safety and effectiveness of the device in fully anti-coagulated patients was demonstrated.

Shing-Chiu Wong, director of cardiac catheterization laboratories at the New York Presbyterian — Weill Cornell Medical Center and a leading clinical participant in the velox CD clinical studies stated, "Velox CD is the world's first metal-based bioabsorbable closure device that is simple to use and highly predictable for femoral access site hemostasis. This innovation should prove to be a significant enhancement to the existing offerings."

For more information: www.transluminal.net

Related Content

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices | December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices | October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices | September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
Overlay Init